Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Reddy

QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it

India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against…

The Economic Times

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The brokerage expects stronger earnings growth, business diversification and new product launches to support both drugmakers.

The Economic Times

Rs 41 lakh cash deposit but no ITR: Bengaluru man claimed his wife and father paid his expenses; ITAT Bangalore refuses relief on this ground

Waseem Ahmed, accountant member and Keshav Dubey, judicial member of ITAT Bangalore, in a recent judgement refused to condone a delay of about 4 years in an unexplained cash deposit case after the taxpayer explained he only got to know about this tax notice while applying for visa for overseas…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target prices

Dr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year to Rs 443 crore and revenue declining 6% to Rs 8,071 crore. Earnings were hit by a Rs 240 crore semaglutide API-related impact, including inventory provisions, while higher…

The Economic Times

Stocks in news: DMart, HCL Tech, ICICI Pru AMC, Dr Reddy’s, NTPC, IndiGo

Markets saw a strong rebound on Friday, driven by global cues and IT earnings. HCL Tech and ICICI Pru AMC will announce their first quarter results today. DMart reported an 11.3% rise in net profit, while Tata Motors launched a new edition. Dr Reddy's faces supply issues, and IndiGo received…

The Economic Times

Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concerns

Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue involving the active pharmaceutical ingredient (API). The company said patient safety and regulatory filings remain unaffected, while an investigation is underway to identify the root cause and restore…

The Economic Times

Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient concern. The firm is actively investigating to identify the source of the problem and is implementing corrective strategies.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturing offer significant future profit pools. Experts anticipate biosimilars could generate substantial revenue, and despite a slow start, GLP-1…

The Economic Times

Stocks in news: Dr Reddy’s, Adani Green, KIMS, JSW Energy, Nestle India

Markets saw a strong rebound on Friday, driven by positive global cues and easing geopolitical tensions. Nifty defended the 23,000 support and reclaimed 23,500, with potential for further gains. Several stocks like Dr Reddy's, Adani Green, and JSW Energy are in focus due to significant corporate developments.

The Economic Times

Dr Reddy's launches oral semaglutide biosimilar Obeda in India

Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This innovative treatment offers patients the ease of a once-daily oral dosage, available in various strengths to effectively enhance glycaemic control. Dr.

The Economic Times

Stocks in news: Vodafone Idea, Indian Oil, Tata Steel, Dr Reddy's, PFC

Markets closed lower amid geopolitical tensions, rupee weakness, and rising inflation. Upcoming week will be sensitive to US-Iran conflict implications for oil and inflation. Vodafone Idea reported a Rs 51,970 crore net profit due to an accounting gain, while Tata Steel and Hindustan Copper saw significant profit growth in Q4FY26.

The Economic Times

Dr. Reddy's Strategic Vision Reiterated Following Strong Q1FY25 Results

Dr. Reddy's reported consolidated revenues of ₹7,673 crores (US$ 921 million) for Q1FY25, marking a 14% year-on-year increase and a 8% sequential growth.

International Business Times

Dr. Reddy’s recalls Sapropterin Dihydrochloride oral solution powder in U.S. due to ‘sub potency’

Dr. Reddy's Laboratories recalls Sapropterin Dihydrochloride Powder due to discoloration, potential health risks, urges consumers to contact physician.

The Hindu

Here are the big stories from Karnataka today

Karnataka Today newsletter: Sowmya Reddy confident of breaking BJP fortress in Bengaluru South, and more

The Hindu

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

BRS wants Congress government to last its full term, die a natural death: KTR

BRS working president K.T. Rama Rao highlights party's achievements and criticizes Congress government in Nalgonda election meeting.

The Hindu

Asad offers full support to Revanth govt.

The Hindu

Congress supports highway blockade on TSPSC paper leak issue

Telangana Congress president Revanth Reddy calls on youth, unemployed to join Oct. 16 highway blockade against govt's failure to conduct TSPSC exams.

The Hindu

JEE results: Six Telugus in top-10 list; topper Chidvilas Reddy from Telangana

Scoring 341 out of 360 marks, Hyderabd zone's Vavilala Chidvilas Reddy topped the IIT entrance exam JEE-Advanced this year

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

BBMP contractors slam government’s decision to freeze bill payments

The State government’s decision to freeze payments of bills for all ongoing and completed works of various departments has now infuriated Bruhat Bengaluru Mahanagara Palike (BBMP) contractors whose payments have been pending since 2021.

The Hindu

Supreme Court sets aside HC stay on inquiry into Amaravati land scam

In a legal victory for the Jagan Mohan Reddy Government, the Supreme Court on May 3 set aside an Andhra Pradesh High Court order issuing a “blanket stay” on an inquiry into the Amaravati land scam and the alleged role of the previous Telugu Desam Party regime.

The Hindu

TTD EO reviews summer arrangements

On the supply of food and water to those in darshan queues, TTD Executive Officer A.V. Dharma Reddy directed the public relations officer to rope in more Srivari seva volunteers at annadanam and laddu counters.

The Hindu

World Economic Forum recognition for Dr. Reddy’s plant

Facility in Bachupally, Hyderabad, now part of Global Lighthouse Network

The Times of India

Mumbai: Powai police once again save money lost in online fraud

MUMBAI: Timely action initiated by the Powai police cyber cell helped 23-year-old Vani Sachdeva get back Rs 46,028 fraudulently siphoned from her bank account after the fraudster had made her download ‘Team Viewer/Quick Support’ on July 30. She received the full amount on Thursday, after the police made the bank…

Benzinga

Eton Pharma Shares Tick Higher After Offloading Hospital Products

Eton Pharmaceuticals Inc (NASDAQ:ETON) has sold its hospital products to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories Ltd (NYSE:RDY), for $50 million. "The sale of our hospital products allows us to focus our resources on our core rare disease business, which is rapidly growing, and also provides an attractive opportunity to monetize…

The Hindu

Nalgonda MP slams Telangana government for ‘intimidating’ sarpanches

The Congress MP alleged that the TRS government is frustrated over the failure of the ongoing 5th phase of the 'Palle Pragathi' programme

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Nasdaq

22,710 stories

Bharatiya Janata Party

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.